Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies is supported by a stronger clinical and reimbursement backdrop for clonoSEQ, as NCCN’s updated multiple myeloma language names the assay directly and expands recommended testing timepoints, which should lift utilization from roughly 2.3 to at least 3.5 tests per patient over time. The company is also benefiting from sustained pricing power, with ASPs at $1,382 per test in Q2'26, a path to $1,400 by YE'26, and gross margins of 71% with a longer-term target of 75%, while MRD revenue guidance of $268M-$278M implies 26%-31% Y/Y growth. Its core MRD business is still early in penetration at about 7%-8%, yet dominant FDA-cleared status, strong EMR integrations, and a potentially more valuable separation from Immune Medicine create a compelling long-term value unlock.

Adaptive Biotechnologies is viewed negatively because its core MRD franchise still faces meaningful clinical adoption risk, with peripheral blood MRD only newly labeled “exploratory” in NCCN guidelines and blood-based testing reaching just 51% of clonoSEQ volumes in Q2’26. The planned separation of the immune medicine business by YE’26 adds execution uncertainty, and there is no guarantee it will happen on that timeline or in a way that benefits the business. Despite growth potential, the stock appears to trade at a significant premium multiple, while reimbursement hurdles, slower-than-expected customer adoption, and competition could constrain the path to durable profitability.